Globus Medical Inc

Globus Medical Inc(GMED)股票分析

$76.710

-2.071 (-2.70%)收盤時

Loading chart…
最高
79.950
開盤
79.350
成交量加權均價
77.72
成交量
1.94M
市值
9.30B
最低
76.490
成交金額
150.80M
企業價值/稅息折舊攤銷前利潤(TTM)
9.09

Globus Medical, Inc. is a global musculoskeletal company. The Company provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The Company offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its segments include Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery, which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities. The Company also provides digital healthcare solutions.

AI 分析 of Globus Medical Inc (GMED)

持有

Globus Medical Inc is currently trading at $76.71, which is below the average analyst price target of $85 from RBC Capital. The stock has a forward P/E ratio of 13.87, indicating it is relatively undervalued compared to its earnings potential. However, insider selling has increased by 389.20% recently, which raises concerns about the stock's short-term outlook. Therefore, while the long-term growth potential remains, the current market sentiment and insider activity suggest a cautious approach, leading to a hold recommendation.

分析師評級(13)

上檔空間 +31.66%
持有
5 買進
7 持有
1 賣出
目前: 76.71
最低
87.00
平均
101.00
最高
114.00

RBC Capital

2026-10-01

目標價

$85

優於大盤

Wells Fargo

2026-08-07

目標價

$99

增持

UBS

2026-07-28

目標價

$82

中性

Truist

2026-07-16

目標價

$100

買進

BMO Capital

2026-07-08

目標價

$94

優於大盤

估值指標

Globus Medical Inc(GMED)目前預期本益比為 13.87,5 年平均預期本益比為 23.36。

預期本益比

低估
5 年均值 P/E
23.36
目前P/E
13.87
高估
28.91
低估
17.81

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
12.01
目前EV/EBITDA
9.09
高估
14.87
低估
9.16

預期股價營收比

合理
5 年均值 P/S
4.17
目前P/S
3.12
高估
5.62
低估
2.73

Alphio AI 對 GMED 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%GMED

$74.60

情境價格

基

基準

基準 · 50%GMED

$69.01

情境價格

悲

悲觀

悲觀 · 25%GMED

$65.33

情境價格

持有 GMED 的大戶

B

Burgundy Asset Management Ltd.

+ 持有GMED

+6.08%

3個月報酬率

A

American Capital Management, Inc.

+ 持有GMED

+1.32%

3個月報酬率

R

Ruane, Cunniff & Goldfarb L.P.

+ 持有GMED

+1.24%

3個月報酬率

N

Nationwide Fund Advisors

+ 持有GMED

-1.49%

3個月報酬率

A

Antipodes Partners Ltd.

+ 持有GMED

-1.82%

3個月報酬率

A

Anchor Capital Advisors LLC

+ 持有GMED

-2.29%

3個月報酬率

事件時間軸

2026-08-31 (ET)

08:30:00

Higgs Boson Health Acquired by Globus Medical

2026-08-26 (ET)

18:00:00

Globus Medical Acquires Higgs Boson Health

2026-05-07 (ET)

18:20:00

Company Reports Q1 Revenue of $759.85M, Beating Expectations

18:20:00

Company Reaffirms FY26 Revenue Guidance of $3.18B to $3.22B

資訊

GMED 常見問題 —— 由 Alphio AI 解答

Globus Medical, Inc. is a global musculoskeletal company. The Company provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The Company offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its segments include Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery, which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities. The Company also provides digital healthcare solutions. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Globus Medical Inc is currently trading at $76.71, which is below the average analyst price target of $85 from RBC Capital. The stock has a forward P/E ratio of 13.87, indicating it is relatively undervalued compared to its earnings potential. However, insider selling has increased by 389.20% recently, which raises concerns about the stock's short-term outlook. Therefore, while the long-term growth potential remains, the current market sentiment and insider activity suggest a cautious approach, leading to a hold recommendation.

13 analysts cover GMED: 5 rate it Buy, 7 Hold and 1 Sell. The average price target is 101.00.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易